#United States #New York #Class Action #Gross Law Firm #aTyr Pharma

A Crucial Notice for aTyr Pharma Shareholders

In a significant development for investors, The Gross Law Firm has released a notice aimed at shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). This notice is particularly vital as it outlines the approaching deadline of December 8, 2025, for shareholders interested in being appointed as lead plaintiffs in an ongoing class action lawsuit against the company.

Background of the Case

The lawsuit revolves around allegations that aTyr Pharma misled investors with overly optimistic statements regarding the capabilities of its drug Efzofitimod. Shareholders who acquired ATYR shares during the specified class period—from November 7, 2024, to September 12, 2025—are encouraged to make contact with The Gross Law Firm to discuss potential participation in the legal proceedings. Notably, becoming a lead plaintiff is not a requirement for any shareholder wishing to pursue recovery under the class action.

The core of the allegations made against aTyr points towards the dissemination of false and misleading information concerning the drug's effectiveness, particularly its potential to allow patients to completely reduce their steroid usage. The situation took a dramatic turn on September 15, 2025, when aTyr held an investor call announcing that its EFZO-FIT clinical study failed to meet the anticipated primary endpoint. This announcement revealed a setback in the company’s research and led to significant financial repercussions for the stock.

Financial Impact on aTyr Pharma

Following the disappointing news, aTyr’s stock price experienced a staggering decline, plummeting from a closing price of $6.03 per share on September 12, 2025, to a mere $1.02 per share on September 15, marking an alarming drop of 83.2% in just one day. Such a dramatic decrease illustrates the impact of false information on investor confidence and stock value, highlighting the reasons for the class action suit.

Steps for Shareholders

Shareholders are strongly urged not to delay in registering for this class action lawsuit. By registering, they will benefit from portfolio monitoring software that will keep them updated on the case's developments. The Gross Law Firm emphasizes that there is no cost or obligation to participate in this legal undertaking.

Why Choose The Gross Law Firm?

Recognized nationally for its commitment to investor rights, The Gross Law Firm has made it its mission to defend those who have suffered losses due to deceitful corporate conduct. The firm persistently advocates for responsible business practices and timely disclosure of material facts, ensuring that companies are held accountable for misleading their investors. The firm firmly believes that those who have been wronged should be afforded the opportunity for recovery through legal means.

Contact Information

Shareholders wishing to learn more or participate in the class action are encouraged to visit The Gross Law Firm's website or contact them directly via email at [email protected] or by phone at (646) 453-8903. The firm’s office is located at 15 West 38th Street, 12th floor, New York, NY 10018.

• ---

This situation serves as a critical reminder of the importance of transparency and accuracy in corporate communication. The continued engagement of aTyr Pharma with its shareholders during this challenging period will be essential as the company works with the FDA to navigate the aftermath of the EFZO-FIT study results. Investors are advised to stay informed and proactive in safeguarding their interests as these proceedings unfold.